Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 109

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 109
---
     |    $ | 17 |     |    $ | 17 |   |     |    $ | 17 |     |    $ | 18 |     |    $ | 18 |     |    $ | 19 |     |    $ | 19 |     |    $ | 20 |
| Unlevered Free Cash Flow (2) |     |    $ | 12 |     |    $ | 13 |   |     |    $ | 13 |     |    $ | 13 |     |    $ | 14 |     |    $ | 14 |     |    $ | 14 |     |    $ | 15 |

| (2) | EBIT is a non-GAAP financial measure defined as net income, plus 
 interest and taxes.                                              |

- 70 -

| (3) | Unlevered free cash flow is a non-GAAP financial measure defined as 
 operating income, less taxes, less change in net working capital.   |

In light of the foregoing factors and the uncertainties inherent in each of the Aadi forecasts, Aadi stockholders are cautioned not to place undue reliance on the Aadi forecasts. Interests of Aadi’s Directors and Executive Officers in the Divestiture When considering the recommendation of Aadi’s board of directors that you vote in favor of the approval of the Divestiture Agreement, you should be aware that our directors and executive officers may have interests in the Divestiture that are different from, or in addition to, the interests of our stockholders generally. Voting and Support Agreements In connection with entering into the Divestiture Agreement, on December 19, 2024, following approval of the Divestiture Agreement by Aadi’s board of directors, the directors and executive officers, as well as certain of their affiliated entities, in each case solely in their capacities as stockholders of Aadi, and one other significant stockholder of Aadi entered into the Support Agreements with Kaken and Aadi. The Support Agreements obligate the directors and executive officers (including certain of their affiliated entities) to vote their respective shares of our common stock in favor of the approval of the Divestiture Agreement and certain related matters, and against certain matters that would reasonably be expected to impede, interfere with, delay, discourage, adversely affect or inhibit the transactions contemplated by the Divestiture Agreement. In (1) evaluating and negotiating the Divestiture Agreement, (2) approving the Divest